Amarin says research shows Miraxion fights brain declines from Alzheimer's, Parkinson's, Huntington's diseases

By E. Janene Geiss

Philadelphia, Nov. 16 - Amarin Corp. plc said Wednesday that its ongoing preclinical research programs show that Miraxion has neuro anti-inflammatory effects, consequently protecting the brain from inflammation often associated with Alzheimer's, Parkinson's and Huntington's diseases.

Miraxion could improve age-related learning and memory decline as those symptoms also are associated with inflammation of the brain, officials said in a company news release.

"Our long-term commitment to neurology research has resulted in these important findings. Determining how Miraxion actually functions in the brain and establishing that Miraxion has neuroprotective effects is fundamental to our understanding of its mechanism of action in neurodegenerative diseases and depressive disorders," Rick Stewart, chief executive officer of Amarin, said in the statement.

The findings were presented in two poster presentations Wednesday at the annual Society for Neuroscience meeting in Washington.

The company also said Wednesday that it has extended its research collaboration with the Institute of Neuroscience at Trinity College, Dublin. The three-year collaboration would focus on further study of Miraxion, Amarin's lead compound.

The project also will investigate potential follow-on compounds as part of Miraxion's life cycle management program. Amarin is developing Miraxion in phase 3 clinical trials for Huntington's disease and has completed several phase 2 trials in depressive disorders, officials said.

London-based Amarin is a neuroscience company focused on development and commercialization of novel drugs for treatment of the central nervous system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.